Merck & Co. Inc. (NYSE:MRK) saw a downside of -0.05% to close Monday at $109.88 after subtracting -$0.06 on the day. The 5-day average trading volume is 8,805,720 shares of the company’s common stock. It has gained $112.49 in the past week and touched a new high 1 time within the past 5 days. An average of 8,020,120 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 9,206,102.
MRK’s 1-month performance is 0.15% or -$1.98 on its low of $108.10 reached on 01/19/23. The company’s shares have touched a 52-week low of $72.88 and high of $115.49, with the stock’s rally to the 52-week high happening on 01/06/23. YTD, MRK has lost -0.96% or -$1.07 and has reached a new high 4 times. However, the current price is down -4.86% from the 52-week high price.
MRK stock investors last saw insider trading activity on Jan 09.Chattopadhyay Sanat (Exe V-P & Pres. MMD) most recently sold 83,994 shares at $112.29 per share on Jan 09. This transaction cost the insider $9,431,915. EVP, Chief HR Officer, MIZELL STEVEN, sold 15,000 shares at a price of $101.42 on Nov 10. Then, on Nov 09, President, U.S. Market Oosthuizen Johannes Jacobus sold 1,795 shares at a price of $103.21 per share. This transaction amounted to $185,262.
MRK stock has a beta of 0.39. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.72 while the price-to-book (PB) in the most recent quarter is 6.26, with the price to cash flow ratio at 33.38.
Merck & Co. Inc.’s quick ratio for the period ended September 29 was 1.20, with the current ratio over the same period at 1.50. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.64, while the total debt to equity was 0.68. In terms of profitability, the gross margin trailing 12 months is 70.90%. The firm’s gross profit as reported stood at $35.08 billion against revenue of $48.7 billion.
For the quarterly period ending September 29 this year, Merck & Co. Inc.’s cash and short-term investments amounted to $103.0 million against total debt of $31.66 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -40.61% to $3.25 billion, while revenue of $3.94 billion was -21.43% off the previous quarter. Analysts expected MRK to announce $1.71 per share in earnings in its latest quarter, but it posted $1.85, representing a 8.20% surprise. EBITDA for the quarter stood at more than $5.07 billion. MRK stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 62.56 billion, with total debt at $31.66 billion. Shareholders hold equity totaling $2.54 billion.
Let’s look briefly at Merck & Co. Inc. (MRK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 44.57% to suggest the stock is trending Neutral, with historical volatility in this time period at 13.69%.
The stock’s 5-day moving average is $109.79, reflecting a -2.11% or -$2.37 change from its current price. MRK is currently trading -1.11% above its 20-day SMA, +25.45% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +8.26% and SMA200 by+31.25%.
Stochastic %K and %D was 24.45% and 19.81% and the average true range (ATR) pointed at 1.87. The RSI (14) points at 48.77%, while the 14-day stochastic is at 24.09% with the period’s ATR at 1.89. The stock’s 9-day MACD Oscillator is pointing at -0.63 and -1.30 on the 14-day charts.
In the most recent analyst report for Merck & Co. Inc. (NYSE: MRK), BofA Securities upgraded it to a Buy rating. They previously had a Neutral rating on the stock.